Erandamooladi Basti along with Ayurvedic Multi Drug Therapy in the Treatment of Chronic Kidney Disease

Efficacy of Ayurvedic Multi Drug Therapy along with Erandamooladi Basti in the Management of Chronic Kidney Disease-An Open Labelled Randomized Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030193

Enrollment

Registered

2021-01-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 2: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 3: N189- Chronic kidney disease, unspecified

Interventions

Intervention1: Basti along with Ayurvedic Multi drug therapy: In Group A patients will be given Ayurvedic oral medications and Panchakarma procedure Basti Oral medications include dipana pachana with

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having signs and symptoms of chronic kidney disease. 2. Patients of both genders between 18-60yrs of age. 3. Patients willing and able to participate. 4. Patients with serum creatinine level between1.2- 6 mg/dl will be included in the study. 5. Patients with serum urea level with in 120mg/dl 6. Patients who are yogya for basti karma.

Exclusion criteria

Exclusion criteria: 1. Female patients having pregnancy, breast feeding or post-delivery period. 2. Patients of end stage renal failure. 3. Patients who are on dialysis treatment for more than 1-month period. 4. Patients who are already operated for renal transplantation and then having nephropathy. 5. Patients of hepato-renal insufficiency or renal insufficiency due to hemodynamic circulatory disorders and CCF. 6. Patients having some serious illness like cardio-vascular diseases, acute mental disorders, serious acute organic diseases, serious chronic co-morbidity, hypo or hyper thyroidism. 7. Patients having haemoglobin concentration below 8gm. 8. Having uncontrolled Hypertension(systolic 9. Patients with serum urea level above 120mg/dl 10. Patients having symptoms of Uremia.

Design outcomes

Primary

Measure	Time frame
Reduction in serum creatinine and increase in eGFRTimepoint: After 4 weeks	—

Secondary

Measure	Time frame
Reduction in signs and symptoms of CKDTimepoint: After 4 week	—

Countries

India

Contacts

Public ContactProf Dr Anup Thakar

IPGT and RA

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026